Creatine riboside is a cancer cell–derived metabolite associated with arginine auxotrophy

Amelia L. Parker, …, Xin Wei Wang, Curtis C. Harris

J Clin Invest. 2022;132(14):e157410. https://doi.org/10.1172/JCI157410.

Graphical abstract

Find the latest version:

https://jci.me/157410/pdf
Creatine riboside is a cancer cell–derived metabolite associated with arginine auxotrophy

Amelia L. Parker,1 Leila Toulabi,1 Takahiro Oike,1 Yasuyuki Kanke,1 Daxeshkumar Patel,1 Takeshi Tada,1 Sheryse Taylor,1 Jessica A. Beck,1 Elise Bowman,1 Michelle L. Reyzer,1 Donna Butcher,1 Skyler Kuhn,4 Gary T. Pauly,3 Kristopher W. Krausz,6 Frank J. Gonzalez,6 S. Perwez Hussain,1 Stefan Ambs,1 Brid M. Ryan,1 Xin Wei Wang,1,7 and Curtis C. Harris1

1Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA. 2National Research Resource for Imaging Mass Spectrometry, Vanderbilt University, Nashville, Tennessee, USA. 3Pathology and Histotechnology Laboratory, Frederick National Laboratory, Frederick, Maryland, USA. 4Center for Cancer Research Collaborative Bioinformatics Resource, 5Chemical Biology Laboratory, 6Laboratory of Metabolism, and 7Liver Cancer Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, USA.

The metabolic dependencies of cancer cells have substantial potential to be exploited to improve the diagnosis and treatment of cancer. Creatine riboside (CR) is identified as a urinary metabolite associated with risk and prognosis in lung and liver cancer. However, the source of high CR levels in patients with cancer as well as their implications for the treatment of these aggressive cancers remain unclear. By integrating multiomics data on lung and liver cancer, we have shown that CR is a cancer cell–derived metabolite. Global metabolomics and gene expression analysis of human tumors and matched liquid biopsies, together with functional studies, revealed that dysregulation of the mitochondrial urea cycle and a nucleotide imbalance were associated with high CR levels and indicators of a poor prognosis. This metabolic phenotype was associated with reduced immune infiltration and supported rapid cancer cell proliferation that drove aggressive tumor growth. CR may be exploited therapeutically. This highlights the potential of CR not only as a poor-prognosis biomarker but also as a companion biomarker to inform the administration of arginine-targeted therapies in precision medicine strategies to improve survival for patients with cancer.

**Introduction**

The reprogramming of cancer cell metabolism is increasingly appreciated for its central role in enabling the growth of the primary tumor as well as its metastasis to distant organs (1–3). These metabolic dependencies may be exploited not only to diagnose cancer but also to target cancer cells, while reducing side effects (3–5). Biomarkers predicting therapeutic efficacy have enabled the administration of targeted therapies to substantially improve the survival of a subset of patients with lung cancer and other poor-prognosis tumors in recent years (6, 7). This demonstrates the potential of metabolic biomarkers as a fundamental component in a precision medicine framework in the treatment of the most aggressive cancers.

Metabolic rewiring of cancer cells occurs through diverse pathways in a highly context-dependent manner (8–14). However, pan-cancer analyses have identified that some metabolic changes are common among different tumor types with distinct etiologies, despite being mediated by myriad transcriptional changes (15, 16). Understanding the etiology of cancer biomarkers and the implications of this metabolic rewiring in tumor progression may further reveal therapeutic opportunities for exploiting these metabolic dependencies to more effectively target aggressive disease (4, 17). For example, argininosuccinate synthase 1 (ASS1), and ornithine transcarbamylase (OCTC) expression status have been used to identify patients who are likely to benefit from arginine-targeted therapies, including arginine deiminase and PEG-arginase therapies, which are showing great promise in improving the sensitivity of a subset of lung and liver tumors to standard-of-care therapies (18–20). Specific companion biomarkers for arginine auxotrophic tumors will be important in identifying patients who will most benefit from this therapy (20).

The metabolite creatine riboside (CR) (Figure 1A) was first identified in an untargeted metabolomics analysis of urine samples from patients with non–small cell lung cancer (NSCLC) and population controls, in whom elevated levels of this metabolite were associated with poor patient survival, particularly in patients with early-stage disease (21). This recently identified metabolite is also associated with an increased risk of developing lung cancer upon, and prior to, a lung cancer diagnosis (22), suggesting that it may result from early metabolic changes.

Recently, urinary CR has also been identified as a biomarker of risk and prognosis in adrenocortical (23) and liver (24) cancer. The metabolic reprogramming of these different tumor types remains diverse (4, 17), yet current data suggest that CR may act as a surrogate marker for a common metabolic program associated with tumorigenesis and tumor progression. However, because the etiology of CR was hitherto unknown, it was unclear whether the metabolic reprogramming associated with CR may be exploited for therapeutic benefit. By combining a multiomics analysis with
Figure 1. CR is enriched in tumors. (A) The chemical structure of CR, creatine, and creatinine. (B) The CR concentration was significantly elevated in tumor (n = 80) compared with nontumor (n = 67) lung tissue. ****P < 0.0001, by Mann-Whitney U test. (C) Representative images of CR distribution in human NSCLC tumor (T) and matched adjacent nontumor (NT) tissue measured by MALDI imaging MS. CR<sup>lo</sup> and a CR<sup>hi</sup> tumors are shown with H&E staining after imaging in the top panel, and MALDI imaging MS signal of CR distribution within the tissue sections is shown in the lower panel. The MALDI imaging MS signal is pseudocolored to indicate CR abundance (range, 0 to 1.01 x 10<sup>3</sup>). Scale bars: 1000 μm. (D) CR enrichment in tumoral compared with nontumoral regions of the lung tissue as measured by the integrated CR signal intensity with MALDI imaging MS. n = 10 matched tumor and nontumor samples. *P < 0.05., by Mann-Whitney U test.

Results

CR is a tumor-derived biomarker. Previously, we had shown that CR levels (Figure 1A) were increased in the urine of patients with NSCLC (21) and increased with tumor size (22). However, CR concentrations could not be precisely quantified in different biospecimens because of the lack of a synthetic standard for this metabolite. We therefore synthesized an analytical standard and developed a precise liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay (25) to quantify the level of CR in NSCLC tumor tissue. Using this assay, we confirmed that the CR concentration was significantly higher in tumor tissue compared with that in adjacent nontumor tissue (P < 0.001, Figure 1B). This more precise LC-MS/MS assay confirmed the significant association of high urinary CR levels with poor prognosis in patients with lung cancer (log-rank P = 0.017, Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/JCI157410DS1) and showed a significant positive correlation of tumoral CR with matched urinary concentrations from the same patient (Spearman’s correlation r = 0.6, P = 0.006, Supplemental Figure 1B), indicating that urinary CR concentrations reflect intratumoral CR concentrations. In contrast, there was no association between tumoral CR levels and the clinicodemographic factors associated with lung cancer outcomes (26) (Supplemental Table 1).

To confirm that CR was enriched in tumor tissue, we spatially mapped CR levels in NSCLC tumor and matched nontumor tissue sections using matrix-assisted laser desorption/ionization (MALDI) imaging MS (Figure 1, C and D, and Supplemental Figure 1C). This confirmed that CR was significantly enriched within tumor tissue compared with levels in immediately adjacent (Supplemental Figure 1G) as well as noninvolved, nontumor (Figure 1, C and D) tissue, thus significantly correlating with our quantitative LC-MS/MS assay (Supplemental Figure 1, D and E) and further supporting the assertion that urinary CR is a surrogate measure of the intratumoral CR concentration. Importantly, CR was not differentially abundant in inflamed, necrotic, or mucinous regions of lung tissue (Supplemental Figure 1F).

The observation of tumor-enriched CR was further validated with the analysis of human cancer cell lines. We detected higher levels of CR in human NSCLC and hepatocellular carcinoma (HCC) cell lines compared with normal and immortalized nontumorigenic primary human bronchial epithelial cells (Figure 2A). Importantly, CR was not detected in conditioned media or cell-
pathway, with the first step being the production of guanidinoacetate in the kidneys through \( \text{L-arginine:glycine} \) amidinotransferase (AGAT) activity, followed by its conversion to creatine by guanidinoacetate \( \text{N-methyltransferase (GAMT)} \) expressed in hepatocytes (27). Creatine is released systemically to be taken up via the creatine transporter SLC6A8 into other cells, such as lung epithelia, which lack the expression of AGAT and GAMT necessary for creatine synthesis. Intracellular creatine can then be enzymatically phosphorylated to phosphocreatine or spontaneously and passively cyclized to creatinine and excreted (27). Quantitative analysis of tumor and adjacent nontumor lung tissue revealed that tissue CR levels positively correlated with both creatine and creatinine levels (Figure 3, A and B), suggesting that CR levels reflect creatine metabolic dysregulation in tumors. The concentration of creatine and creatinine in tumor tissue exceeded that of CR by approximately 30- and 5-fold, respectively, indicating that CR constituted a relatively small proportion of the total creatine metabolite pool. These data support the notion that CR is a tumor-derived metabolite and potential biomarker of dysregulated creatine metabolism.

Creatine and creatinine emerged as strong candidate metabolic precursors for the creatine moiety of CR because of their structural similarity (Figure 1A) and correlation with CR levels (Figure 3, A and B). To understand the metabolic synthesis of CR, heavy carbons were traced from \( ^{13}\text{C-creatine} \) and \( ^{13}\text{C-creatinine} \) supplied in cell culture media to the intracellular CR pool. Despite the intracellular abundance of exogenously supplied \( ^{13}\text{C-creatine} \) free samples (Figure 2A), indicating that CR is likely a product of cellular metabolism. We found no association between CR levels and intracellular concentrations of creatine or creatinine (Supplemental Figure 1, H and I) or with intracellular concentrations of creatine riboside, the low-abundance cyclized form of CR (Supplemental Figure 1J). The median intracellular CR concentration (0.213 pmol/10^6 cells) was used to stratify NSCLC and bronchial cell lines into CRhi and CRlo cell lines (Supplemental Figure 1K) for further interrogation of the metabolic characteristics associated with high CR levels.

To understand the intracellular kinetics of CR production, we monitored the levels of the metabolite in CRhi cells over time. We found that the intracellular CR concentration increased over time, with a significant increase in the levels only after at least 1 population-doubling period (at \( t = 48 \) h) (Figure 2, B and C), suggesting that a complete cell cycle occurred before CR levels began to increase. Supplementation of CRhi and CRlo cell lines with CR itself did not alter their proliferation rate (Supplemental Figure 2, A–D), despite the detection of extracellularly supplied CR within the intracellular metabolite pool (Supplemental Figure 2E), indicating that CR is a cancer cell–derived biomarker that accumulates with cell proliferation but does not itself induce functional effects.

CR is formed from creatinine. Structurally, CR is a ribosylated form of creatine, leading us to hypothesize that CR may reflect dysregulated creatine metabolism within lung and other tumors. In healthy tissues, creatine is synthesized from arginine in a 2-step pathway, with the first step being the production of guanidinoacetate in the kidneys through \( \text{L-arginine:glycine} \) amidinotransferase (AGAT) activity, followed by its conversion to creatine by guanidinoacetate \( \text{N-methyltransferase (GAMT)} \) expressed in hepatocytes (27). Creatine is released systemically to be taken up via the creatine transporter SLC6A8 into other cells, such as lung epithelia, which lack the expression of AGAT and GAMT necessary for creatine synthesis. Intracellular creatine can then be enzymatically phosphorylated to phosphocreatine or spontaneously and passively cyclized to creatinine and excreted (27). Quantitative analysis of tumor and adjacent nontumor lung tissue revealed that tissue CR levels positively correlated with both creatine and creatinine levels (Figure 3, A and B), suggesting that CR levels reflect creatine metabolic dysregulation in tumors. The concentration of creatine and creatinine in tumor tissue exceeded that of CR by approximately 30- and 5-fold, respectively, indicating that CR constituted a relatively small proportion of the total creatine metabolite pool. These data support the notion that CR is a tumor-derived metabolite and potential biomarker of dysregulated creatine metabolism.

Creatine and creatinine emerged as strong candidate metabolic precursors for the creatine moiety of CR because of their structural similarity (Figure 1A) and correlation with CR levels (Figure 3, A and B). To understand the metabolic synthesis of CR, heavy carbons were traced from \( ^{13}\text{C-creatine} \) and \( ^{13}\text{C-creatinine} \) supplied in cell culture media to the intracellular CR pool. Despite the intracellular abundance of exogenously supplied \( ^{13}\text{C-creatine} \) free samples (Figure 2A), indicating that CR is likely a product of cellular metabolism. We found no association between CR levels and intracellular concentrations of creatine or creatinine (Supplemental Figure 1, H and I) or with intracellular concentrations of creatine riboside, the low-abundance cyclized form of CR (Supplemental Figure 1J). The median intracellular CR concentration (0.213 pmol/10^6 cells) was used to stratify NSCLC and bronchial cell lines into CRhi and CRlo cell lines (Supplemental Figure 1K) for further interrogation of the metabolic characteristics associated with high CR levels.

To understand the intracellular kinetics of CR production, we monitored the levels of the metabolite in CRhi cells over time. We found that the intracellular CR concentration increased over time, with a significant increase in the levels only after at least 1 population-doubling period (at \( t = 48 \) h) (Figure 2, B and C), suggesting that a complete cell cycle occurred before CR levels began to increase. Supplementation of CRhi and CRlo cell lines with CR itself did not alter their proliferation rate (Supplemental Figure 2, A–D), despite the detection of extracellularly supplied CR within the intracellular metabolite pool (Supplemental Figure 2E), indicating that CR is a cancer cell–derived biomarker that accumulates with cell proliferation but does not itself induce functional effects.

CR is formed from creatinine. Structurally, CR is a ribosylated form of creatine, leading us to hypothesize that CR may reflect dysregulated creatine metabolism within lung and other tumors. In healthy tissues, creatine is synthesized from arginine in a 2-step pathway, with the first step being the production of guanidinoacetate in the kidneys through \( \text{L-arginine:glycine} \) amidinotransferase (AGAT) activity, followed by its conversion to creatine by guanidinoacetate \( \text{N-methyltransferase (GAMT)} \) expressed in hepatocytes (27). Creatine is released systemically to be taken up via the creatine transporter SLC6A8 into other cells, such as lung epithelia, which lack the expression of AGAT and GAMT necessary for creatine synthesis. Intracellular creatine can then be enzymatically phosphorylated to phosphocreatine or spontaneously and passively cyclized to creatinine and excreted (27). Quantitative analysis of tumor and adjacent nontumor lung tissue revealed that tissue CR levels positively correlated with both creatine and creatinine levels (Figure 3, A and B), suggesting that CR levels reflect creatine metabolic dysregulation in tumors. The concentration of creatine and creatinine in tumor tissue exceeded that of CR by approximately 30- and 5-fold, respectively, indicating that CR constituted a relatively small proportion of the total creatine metabolite pool. These data support the notion that CR is a tumor-derived metabolite and potential biomarker of dysregulated creatine metabolism.

Creatine and creatinine emerged as strong candidate metabolic precursors for the creatine moiety of CR because of their structural similarity (Figure 1A) and correlation with CR levels (Figure 3, A and B). To understand the metabolic synthesis of CR, heavy carbons were traced from \( ^{13}\text{C-creatine} \) and \( ^{13}\text{C-creatinine} \) supplied in cell culture media to the intracellular CR pool. Despite the intracellular abundance of exogenously supplied \( ^{13}\text{C-creatine} \)
or $^{13}$C-creatinine, only $^{13}$C-creatinine, and not $^{13}$C-creatine, resulted in enrichment of the heavy carbon label within CR (Figure 3, C and D), indicating that creatinine was the precursor for CR.

To determine whether the creatinine that formed CR was synthesized from arginine or imported from the extracellular environment, NSCLC cells were cultured in media containing either $^{13}$C-creatine or its biosynthetic precursor $^{13}$C-arginine, and the incorporation of the heavy carbon label into CR was monitored by LC-MS/MS. CR was labeled when cells were cultured in $^{13}$C-creatine but not $^{13}$C-arginine (Figure 3, E and F), revealing that creatinine biosynthesis was not a major contributor to the CR pool but that instead creatinine imported from the extracellular environment was the CR precursor.

When we extended this analysis to creatinine concentrations below and above (5 μM–1 mM) the physiological plasma concentration of creatinine (75 μM) (28) using $^{13}$C-creatinine, we found a positive linear relationship between $^{13}$C-CR and $^{13}$C-creatine levels in CR$^{+}$ cell lines (Figure 3, G and H), confirming the direct conversion of creatinine into CR. We observed similar results in CR$^{−}$ cells (Supplemental Figure 2F) with cell lines supplemented with up to 5 mM $^{13}$C-creatinine, despite comparable concentrations of intracellular creatinine between CR$^{+}$ and CR$^{−}$ cells (Figure 3J). These findings thus confirmed that CR was derived from creatinine and that both tumorigenic and nontumorigenic cell lines, regardless of their endogenous CR levels, were capable of producing CR. Importantly, cells with high endogenous CR levels more readily converted creatinine to CR.

The conversion of creatinine to CR was not immediate but occurred gradually over time following 1 complete cell cycle (doubling time was ~24 h) (Figure 3K). This resembled the rate of increase in CR levels with each population doubling (Figure 2, B and C), indicating that creatinine ribosylation, and not creatinine availability, was the rate-limiting step for the conversion of creatinine to CR.

The ribosylation of creatinine from pentose phosphate pathway products is the rate-limiting step in CR formation. Ribose itself or ribose intermediates derived through the pentose phosphate or nucleotide metabolism pathways are major sources of ribosylation substrates in cells. Culturing cell lines in $^{13}$C-glucose but not $^{13}$C-ribose or $^{13}$C-cytidine resulted in enrichment of the $^{13}$C label in CR (Figure 4A), indicating that ribose products derived from glucose metabolism through the pentose phosphate pathway (PPP) were the likely precursors of CR. Consistently, we found that glucose starvation abrogated CR production (Figure 4, B and C). As expected, the rate of $^{13}$C-CR formation from $^{13}$C-glucose increased progressively after 1 complete cell cycle (Figure 4D), and resembled the time course of CR formation from creatinine (Figure 2, B and C, and Figure 3K), confirming that the ribosylation of creatinine was the rate-limiting step in CR formation.

To confirm that PPP activity is required for CR formation, cells were treated with 6-aminonicotinamide (6-AN), a competitive inhibitor of 3-phosphoglycerate dehydrogenase (PHGDH), which catalyzes the rate-limiting step of the PPP, and the levels of CR were monitored by LC-MS/MS. Inhibition of PHGDH with 6-AN markedly reduced the enrichment of $^{13}$C within CR (Figure 4E and Supplemental Figure 3A), as well as the production of endogenous $^{12}$C-CR (Figure 4E and Supplemental Figure 3A), validating the source of the ribose moiety as a product of the PPP.

Both the oxidative and nonoxidative arms of the PPP can contribute to the formation of ribose intermediates. Culturing cells in 1,2-$^{13}$C$_2$-glucose resulted in (M+1) and (M+2) labeling of the intracellular ribose pool and formed both (M+1) CR and (M+2) CR, with (M+1) CR predominating (Figure 4, F and G). This indicates that, while both the oxidative and nonoxidative PPs produced the precursor to the ribose moiety of CR, the oxidative PPP was the major producer of the ribose moiety precursor. The oxidative PPP culminates in the production of ribose-5-phosphate, which is activated for conjugation with other metabolites or is converted to phosphoribosyl pyrophosphate (PRPP) for ribonucleotide production and is the likely ribosylation substrate in the formation of CR.

Incubation of creatinine and PPP products in human urine samples under various conditions did not produce CR (Supplemental Figure 3B), confirming that CR was produced through an intracellular catalyzed process and was not an extraction artifact.

Together, these data indicate that creatinine and PPP products are the precursors for the metabolite CR and that the conjugation of PPP metabolites with creatinine is the rate-limiting step in the production of CR.

CR is associated with altered nitrogen metabolism. Having established the metabolite precursors for CR, we sought to determine the metabolic processes in tumor cells that would give rise to high CR levels. Having demonstrated a strong positive correlation of urinary and tumoral CR levels, we focused on the association of tumoral CR with the metabolic features of tumors. Gene set enrichment analysis (GSEA) of global gene expression profiles in CR$^{+}$ and CR$^{−}$ NSCLC tumors using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database, which contains a wide range of metabolic pathways, identified several significantly altered pathways (Figure 5, A and B, and Supplemental Table 2). These included nonmetabolic pathways such as those for ECM-receptor interactions, focal adhesions, and NK cell cytotoxicity, which were significantly enriched in CR$^{−}$ tumors, and for the spliceosome, which was significantly enriched in CR$^{+}$ tumors (Supplemental Table 2). Of all the metabolic pathways, the pathway for downregulation of arginine and proline metabolism was identified as the most significantly altered metabolic pathway in CR$^{+}$ tumors (Figure 5A and Supplemental Figure 4A). Urea cycle (CPSP, NAGS, ASSI) and creatine metabolism (CKM, GATM) enzymes, which are directly interconnected to arginine synthesis and catabolism (5), were identified as the most significantly differentially expressed genes in this pathway, and leading-edge analysis found that these genes overlapped with other significantly downregulated metabolic pathways, namely those for limonene and pinene metabolism and nitrogen metabolism and histidine metabolism (Figure 5A). Together, this suggests that the altered expression of these genes is central to the metabolic features of CR$^{+}$ tumors.

In accordance with CR being a product of the PPP (Figure 4), we found that CR$^{+}$ tumors were also enriched for the pentose interconversion pathway, with the core enriched genes including the PPP enzyme genes RPE and XYLB and the genes in the UGT family of enzymes, including UGT1A8, UGT1A3, and UGDH (Figure 5B and Supplemental Figure 4E). Upregulation of XYLB in CR$^{+}$ tumors also contributed to upregulation of the glucuronate biosynthesis and glycosaminoglycan synthesis pathways in CR$^{+}$ tumors (Figure 5B).
Figure 3. Creatinine is a metabolic precursor of CR. Correlation of CR with creatine (A) and creatinine (B) within NSCLC tumor tissues (Spearman’s correlation: n = 147 tissue samples). (C and D) Fractional enrichment of CR labeling from [13C]-creatine or [13C]-creatinine in H460 (C) and A549 (D) cells. Data indicate the mean ± SEM of 3 independent experiments. ****P < 0.0001, by 1-way ANOVA with Holm-Šidák correction for multiple comparisons. (E and F) Fractional enrichment of CR labeling from [13C]-creatine or [13C]-arginine in H460 cells (E) and A549 cells (F). Data indicate the mean ± SEM of 3 independent experiments. ****P < 0.0001, by 1-way ANOVA with Holm-Šidák correction for multiple comparisons. The [13C]-creatinine treatment group is replicated from C and D. (G and H) CR levels increased with increasing creatinine supplementation as measured by the fractional enrichment of CR labeling from [13C]-creatinine in H460 (G) and A549 (H) cells. Dotted line indicates endogenous serum levels of creatinine (75 μM) in humans. Data indicate the mean ± SEM of 3 independent experiments. (I) Intracellular CR concentrations in CRlo (blue) and CRhi (red) cell lines with increasing concentrations of exogenously supplied creatinine. Data indicate the mean ± SEM of 3 independent experiments. (J) Intracellular creatinine concentrations in CRlo (blue) and CRhi (red) cell lines with increasing concentrations of exogenously supplied creatinine. Data indicate the mean ± SEM of 3 independent experiments. (K) Time course of the fractional enrichment of CR labeling from [13C]-creatinine over 72 hours in H460 cells. Data indicate the mean ± SEM of 3 independent experiments.
Using gene set variation analysis (GSVA) of the core enriched genes from the PPP (XYLB, RPE, and TALDO1) and arginine metabolism (CPS1, NAGS, ASS1, CKM, AOC1, and GATM), together with the rate-limiting enzymes of the PPP (G6PD and PRPS1), we confirmed that the PPP was upregulated (Figure 5, C and D) and that arginine metabolism was downregulated (Figure 5, E and F) in CRhi tumors compared with CRlo tumors in both the lung and liver tumors (Supplemental Tables 3 and 4). Applying the PPP signatures to the lung adenocarcinoma, squamous NSCLC, and HCC The Cancer Genome Atlas (TCGA) cohorts confirmed that the PPP was significantly upregulated in tumor tissue compared with nontumor tissue across all cancer types (Supplemental Figure 4, H–J).

Importantly, in the NCI-MD cohort, genes of the mitochondrial component of the urea cycle, namely CPS1, NAGS, and OTC, were the most significantly differentially expressed genes of the arginine metabolism pathway in CRhi tumors, and the mitochondrial component of the urea cycle pathway was identified as significantly downregulated in CRhi lung and liver tumors (Figure 5, G and H). Metabolic flux through the urea cycle relies on activity of both the mitochondrial and cytosolic components of the cycle. A focused examination of urea cycle enzyme expression across lung and liver cancer subtypes revealed repression of the mitochondrial urea cycle mediated through different gene expression programs that functionally downregulate mitochondrial urea cycle activity. In NSCLC and intrahepatic cholangiocarcinoma of the liver cancer, the mitochondrial urea cycle enzyme CPS1 was downregulated either directly (Figure 5, I and K) or via reduced expression of NAGS, the enzyme that produces its essential cofactor N-acetylglutamate, respectively (Figure 5, J and L, and Supplemental Figure 4B). Projection of the CPS1 plus NAGS expression score onto TCGA squamous NSCLC confirmed that CPS1 plus NAGS expression was significantly lower in tumor compared with nontumor tissue, while a substantial proportion of lung adenocarcinoma tumors have low CPS1 plus NAGS expression compared with nontumor tissue (Supplemental Figure 4, K and L). Conversely, in the HCC subtype of liver cancer, CRhi tumors showed high expression of CPS1 compared with OTC (Figure 5, M and N), a gene expression pattern that prevents continued conversion of carbamoyl phosphate into citrulline to proceed through the urea cycle and overall results in downregulated mitochondrial urea cycle activity (29). Both downregulated CPS1 activity (CRhi NSCLC and intrahepatic cholangiocarcinoma tumors) or OTC activity (CRhi HCC tumors) result in severe arginine auxotrophy (29) and therefore reflect a common repression
of mitochondrial urea cycle metabolism in these different cancer subtypes. Consistent with this, we observed downregulation of the mitochondrial urea cycle in tumor tissue compared with non-tumor tissue in the TCGA HCC cohort (Supplemental Figure 4M).

In order to validate the metabolic pathways and transcriptional features associated with CR production in additional data sets, we applied these transcriptional signatures to RNA-Seq data from TCGA lung adenocarcinoma, squamous NSCLC, and HCC cohorts and defined CRhi-like tumors as those belonging to the highest tertiles for the PPP and mitochondrial urea cycle dysfunction, whereas CRlo-like tumors were defined as those belonging to the lowest tertiles for the PPP and mitochondrial urea cycle dysfunction. GSEA comparing CR hi-like and CR lo-like tumors recapitulated the enrichment of the PPP, glucuronate interconversions, and depletion of arginine and proline metabolic pathways in CRhi tumors from these different tumor types (Supplemental Figure 4, N–S).

Consistently, CRhi cells (A549, H460), unlike CRlo cells (H322, H1299, H1650), were highly auxotrophic for arginine, as indicated by a significant reduction in cell proliferation when cultured in arginine-free conditions (Figure 6A). Supplementation with citrulline, but not ornithine or the nitric oxide donor sodium nitrite, restored the growth of the CR hi cell lines in these arginine-free conditions (Figure 6A), confirming that the mitochondrial component, rather than the cytosolic component of the urea cycle pathway, was unable to support continued proliferation in the absence of exogenous arginine. Consistent with repression of mitochondrial urea cycle activity, CR hi cell lines had high steady-state levels of ornithine (Figure 6B), whereas citrulline (Figure 6C), arginine (Supplemental Figure 5A), and argininosuccinate...
with loss of flux through the mitochondrial component of the urea cycle and renders these cells dependent on exogenous arginine to maintain proliferation.

The CR metabolic phenotype is characterized by biased nucleotide metabolism. Recent studies have highlighted that urea cycle metabolism is dysregulated in subsets of multiple tumor types, including NSCLC and liver cancer, for which CR has prognostic importance and has the potential to create multiple metabolic vulnerabilities by inducing changes in amino acid and nitrogen metabolism (5, 30).

To further characterize the global metabolic vulnerabilities associated with dysregulated urea cycle metabolism in CR hi NSCLC tumors, we performed global metabolic profiling of the tumor tissues for which intratumoral CR levels had been quantified. Ingenuity Pathway Analysis identified that CR levels were significantly correlated with altered nitrogen metabolism and, in particular, the purine metabolism, amino acid biosynthesis, urea cycle, and oxidative phosphorylation pathways (Figure 6A), as predicted by the transcriptional profiles of these tumors (Figure 4).

Purine metabolism was the most significantly correlated metabolic change observed in CR hi NSCLC tumors (Figure 7A), supported by significant enrichment of purine compared with immortalized bronchial epithelial cells (HBET1, black). Data indicate the mean ± SEM of 2–3 independent experiments. *P < 0.05 and ***P < 0.001, by 1-way ANOVA with Dunnett’s multiple-comparison correction.
resulting in a purine/pyrimidine nucleotide imbalance. In this way, CR levels were a surrogate for the activity of the mitochondrial urea cycle in tumors. The precise mechanism by which a CPS1-mediated purine/pyrimidine nucleotide imbalance leads to the ribosylation of creatinine to produce CR remains the subject of ongoing studies. Metabolomics analysis of CR hi tumors also identified significant dysregulation of oxidative phosphorylation (Figure 7A), which regulates nicotinamide adenine dinucleotide (NAD+) levels for nucleotide synthesis (31–33). To understand how central carbon metabolism may be rewired to support purine nucleotide synthesis, we performed 13C-glucose tracing experiments, which confirmed that CR hi cell lines had significant enrichment of 13C into tricarboxylic acid intermediates (Figure 8B and Supplemental Figure 6, A–D). Importantly, CRhi cell lines had increased aspartate labeling from glucose compared with CR lo cell lines (Figure 8C). Aspartate is a limiting metabolite in nucleotide synthesis (32, 33), such that increased aspartate synthesis from elevated tricarboxylic acid and oxidative phosphorylation activity in CRhi NSCLC tumors would support a purine synthesis bias. This is further supported by increased oxidative phosphorylation in CR hi cell lines compared with CRlo cell lines (Figure 8D). Similarly, depletion of glutamine, a metabolite that enables high tricarboxylic activity through anaplerotic reactions, significantly reduced CR levels (Figure 8, E and F), further indicating a role for high tricarboxylic acid activity in supporting biased nucleotide synthesis in CRhi tumors.

Together, these findings indicate that CR tumors have a distinct metabolic phenotype compared with that of CR lo tumors. In
The CR metabolic phenotype supports rapid proliferation. Having established the metabolic remodeling in CRhi tumors, we sought to gain further insight into the potential oncogenic reprogramming underlying this remodeling. Whole-exome sequencing of NSCLC tumors identified driver mutations at a frequency similar to that previously reported (Supplemental Figure 8A) (34), however, there were no driver mutations uniquely associated with CRhi tumors (Supplemental Figure 8B). This is consistent with findings in cell lines, in which CR levels were also not significantly associated with known driver mutations (Supplemental Table S5). Diverse mutational events probably contribute to the high CR phenotype, analogous to the myriad transcriptional changes that converge on individual dysregulated pathways across multiple cancer types (15).

The purine/pyrimidine nucleotide bias we identified in CRhi tumors has the potential to alter antigen presentation in the tumor microenvironment to influence the immunological landscape and response to immune checkpoint therapy (30). Cell-type deconvolution of the bulk RNA-Seq expression data from NSCLC tumors identified a significant reduction in monocytes and CD4+ memory resting T cells in CRhi lung tumors (Supplemental Figure 8C). Multiplexed immunofluorescence staining supported these findings, identifying a strong negative correlation between CR levels measured by MALDI imaging MS and the number of CD68+ (Spearman’s $r = –0.72$, $P = 0.023$) and CD8+ T cells (Spearman’s $r = –0.65$, $P = 0.049$) (Supplemental Figure 8D). Comparatively, there was no significant association of CR levels with PD-1+ cells in this analysis (Supplemental Figure 8D). Together, this analysis indicates intrinsic reduction in the level of CD68+ macrophages and CD8+ T cells in CRhi tumors. The reduced levels of tumor-infiltrating macrophages and CD8+ T cells may contribute to a worse prognosis in CRhi tumors (35, 36), warranting further interrogation of these relationships in larger cohorts.

To gain insight into the contribution of the CR-associated metabolic phenotype to tumor progression, we examined nonmetabolic pathways identified as significantly up- and downregulated in CRhi compared with CRlo NSCLC tumors by GSEA. This revealed that CRhi tumors were significantly enriched for cell-cycle–regulating genes (Figure 9A), with core enrichment of regulators of G1/S transition (e.g., $CDK6$, $CDC6$, $CCNE1$) and early S-phase progression pathways (Supplemental Figure 7).
Discussion

Metabolic rewiring of cancer cells supports tumor progression and represents a potential source of biomarkers for cancer detection and treatment response. Understanding the origin of metabolic biomarkers enables the personalized and rational design of precision medicine treatments that exploit metabolic vulnerabilities in tumors. This study has revealed that CR, a recently identified prognostic metabolite detected in urine, serum, and tissue biospecimens, is a tumor-derived biomarker of altered urea cycle and PPP activity that promotes tumor growth across multiple tumor types. Our analysis identifies CR as a tumor-derived metabolite detectable in serum and plasma biospecimens, building on previous studies of CR as a urinary biomarker of risk and prognosis in lung, liver, and adrenocortical carcinoma (21–24). The strong positive correlation of urinary CR levels with tumoral CR levels enabled us to dissect the metabolic profile of CRhi tumors directly at the tissue level. Furthermore, as urinary CR levels strongly correlated with tumoral CR levels, the detection of CR as a diagnostic and prognostic biomarker could be conducted in a minimally invasive manner by analyzing liquid biopsies. In this way, CR levels may assist in identifying patients with NSCLC or liver cancer at high risk of relapse.

Together, these results identify CR as a biomarker of urea cycle dysfunction and nucleotide imbalance in multiple cancer types. This metabolic rewiring drives highly proliferative primary tumors to promote tumor progression, resulting in poor patient survival (Figure 10D).
CR is not confined to cancer cells, the reprogramming of these metabolic pathways in cancer cells enables them to produce higher levels of this metabolite than nontransformed cells. By integrating the pentose phosphate and urea cycle pathways, CR levels amplify the disparity between tumoral and healthy metabolism, thereby underpinning its potential utility as a sensitive diagnostic and prognostic biomarker (21, 22, 24).

This study reveals that high CR levels reflect a diversion of mitochondrial urea cycle metabolites to support nucleotide synthesis, resulting in urea cycle dysfunction and arginine auxotrophy (30). The urea cycle enzyme CPS1 is central to this metabolic diversion in CRhi tumors. Increased CPS1 expression is associated with dysregulated creatine metabolism and PPP activity in NSCLC (29, 39), supporting the importance of this enzyme in CR production. The high expression of CPS1 relative to that of OTC in CRhi HCC observed in our study concurs with global proteomics analysis of tumor and nontumor tissue (40) and has been shown to result in carbamoyl phosphate diversion to the cytosol to enhance CAD activity (5, 29), which is negatively associated with prognosis (41–43). Furthermore, the association of CR with altered urea cycle activity is supported by recent studies showing that creatinine levels and creatine phosphocreatine pathway activity are regulated by urea cycle activity (44). Urea cycle dysfunction supports anabolic metabolism through the diversion of metabolites toward nucleotide synthesis (5, 30, 37, 45), thus fueling the high rates of cell proliferation associated with high CR levels. A recent study of breast cancer revealed that arginine starvation also suppresses oxidative phosphorylation and inhibits cellular proliferation via nucleotide depletion (46), thereby supporting the association of high CR levels with arginine auxotrophy, a purine/pyrimidine bias, and cancer cell proliferation. CR is also a surrogate for hyperactivation of the PPP. The widespread dysregulation of the pentose and glucuronate interconversion pathways in multiple tumor types, albeit by different transcriptional mechanisms (15), suggests that CR may

Figure 10. CRhi tumors are highly proliferative. (A) Ki67 immunostaining of tumors (DAPI is shown in blue and Ki67 in gray) indicates that CRhi tumors were enriched in Ki67+ cells. Scale bars: 1000 μm (MALDI mass spectrometry imaging of creatine riboside) and 500 μm (Ki67 staining). Images are representative of 10 matched tumor and nontumor tissues. (B) High-magnification images from A. Scale bar: 100 μm. (C) Scatter plot shows a correlation (Spearman’s) of the proportion of Ki67+ cells relative to the CR signal determined by MALDI imaging MS. (D) Schematic representation of the consequences of metabolic rewiring associated with CRhi tumors.
be useful as a predictive and prognostic biomarker in diverse cancer types extending beyond lung and liver cancers.

At the nexus of the urea cycle, pentose phosphate and nucleotide synthesis pathways, CR reflects highly integrated and coordinated regulation of these metabolic pathways. For example, flux through the cytosolic urea cycle pathway, which remains intact in CR<sup>hi</sup> tumors, activates glycolysis, and supports the production of ribose-5-phosphate by the PPP (47), while intermediates of de novo synthesis of purine nucleotides, such as 5-aminoimidazole-4-carboxamide riboside (AICA riboside), also stimulate catabolism of glucose to pentose products (48). Notably, PRPS1, which is upregulated in CR<sup>hi</sup> NSCLC tumors, couples the PPP with de novo purine nucleotide synthesis, thereby directly linking the PPP with the purine nucleotide bias seen in these tumors. It is well established that these metabolic changes support hyperproliferative cancer cell phenotypes (5, 30, 37, 45, 49) and thus underlie the association of CR with aggressive, rapidly proliferating tumors.

The importance of cell proliferation in CR production may explain why CR levels are elevated many years before a lung cancer diagnosis (22), when hyperplasia is probably already evident (50–52).

Our rigorous analysis of human biospecimens and in vitro studies failed to find evidence that CR could be spontaneously and passively formed in cells, indicating instead that CR synthesis is likely enzymatically catalyzed, or its formation is driven by electrochemical conditions unique to the intracellular environment. CR production requires cell proliferation, and the compartmentalization of metabolic precursors or enzymatic reactions during specific cell-cycle phases in proliferating cells may explain CR kinetics. We propose a model in which a purine/pyrimidine synthesis bias during cell proliferation increases nucleotide metabolism and thereby increases the availability of activated ribose substrates for the ribosylation of creatinine to form CR. This process may involve enzymes involved in nucleotide synthesis that show altered specificity due to a purine/pyrimidine nucleotide bias. The precise mechanism of creatinine ribosylation remains the subject of ongoing studies in the laboratory.

The association of CR with urea cycle dysfunction and altered nucleotide synthesis has substantial therapeutic implications. The arginine auxotrophy induced by urea cycle dysfunction renders CR<sup>hi</sup> tumors sensitive to arginine-targeted therapies, which are a rapidly emerging and promising approach in the treatment of NSCLC, breast, pancreatic, and liver cancers, among others (5). The majority of trials testing recombinant human arginase or arginine deiminase therapies have used loss of ASS1 expression as an indicator of therapeutic efficacy (5, 19), however, ASS1 expression levels alone are not always indicative of therapeutic activity (53). Our analysis suggests that CR levels within tumors or liquid biopsies may be a companion diagnostic for arginine auxotropic tumors that express ASS1 but may also benefit from arginase-based therapies. In this way, a CR biomarker identifies a subset of ASS1-competent tumors that are likely to respond to arginine-targeted therapies. Furthermore, since CR levels reflect the contribution of multiple genes to the dysregulation of the urea cycle, CR levels may identify more cancer patients who are likely to respond to arginase-based therapies compared with the current rationale of using ASS1 expression alone, which fails to identify subsets of tumors that will be sensitive to this emerging therapy (54). Similarly, the association of CR levels with a purine/pyrimidine bias suggests that CR<sup>hi</sup> tumors are also likely to be sensitive to existing nucleotide imbalance–targeting therapeutics such as methotrexate, whereas pyrimidine synthesis–targeting therapeutics such as pemetrexed and 5-fluorouracil (55) are likely to be more effective in CR<sup>hi</sup> HCC tumors. The association of high CR levels with reduced macrophage and CD8<sup>+</sup> immune cell infiltrates suggests that CR levels may not only reflect an altered immunological landscape, as seen in tumors with urea cycle dysfunction (30), but the potential of arginine-targeted therapies to modulate immunotherapy efficacy in lung and other cancers. Further investigations of these findings in larger, immunotherapy-focused patient cohorts are warranted.

Our analysis clearly indicates that CR levels were enriched in tumor compared with nontumor tissue. Our quantitative analytical method allows for sensitive detection at very low concentrations of CR (25) and is therefore capable of detecting very low concentrations of this metabolite in urinary samples from noncancer patients. Our data indicate that noncancerous cells, namely immortalized bronchial epithelial cells, are capable of producing CR when substituted with creatinine and therefore raise the possibility that normal cells may contribute to the low CR signal seen in noncancer patients. However, the conditions under which proliferating epithelial cells would be exposed to the supraphysiological creatinine concentrations required to produce low amounts of CR are unclear. Our data indicate that CR is produced by highly proliferative cells with hyperactivation of the PPP and urea cycle dysfunction, which are active metabolic pathways in many normal cell types. Benign lung nodules and premalignant lesions are both associated with hyperplastic changes in lung tissue (56) and represent potential sources of CR signal in noncancer patients. Importantly, benign lung nodules are detected at relatively high frequency in lung cancer screening trials (57, 58). Furthermore, premalignant lung lesions have a high regression rate, with 66% of lesions spontaneously resolving (59), suggesting that a large proportion of patients with premalignant lesions may never be identified in the population, particularly in populations with a high proportion of current and former smokers, despite the theoretical potential for these lesions to produce detectable amounts of CR. Similarly, our previous analysis of urinary CR in population controls as part of a prospective analysis identified an association of higher CR levels in current compared with former smokers in noncancer controls, although there was no association with pack years (22). This suggests that acute smoke exposure in the lung may contribute to CR production. Tobacco smoke exposure has been associated with altered serum concentrations of arginine, ornithine, and glutamate as well as other lipid metabolites, although the mechanisms underlying these observations remain unknown (60). Therefore, smoking-associated alterations in the levels of these metabolites may modulate the low levels of CR detected in population controls. Tobacco smoke exposure also promotes a proinflammatory response in the lung that activates pneumocyte proliferation (61, 62). Similarly, ROS induced in the lung as a result of tobacco smoke exposure also activate the NFE2-like bZIP transcription factor 2 (NRF2) pathway (63), which has been shown to upregulate the PPP (64), potentially linking tobacco smoke exposure to inflammation-associated metabolic reprogramming that
may contribute to CR production. Although CR levels were not higher in inflamed intratumoral regions in our analysis, it remains to be determined whether widespread lung inflammation from acute tobacco smoke exposure may contribute to the very low CR levels detected in noncancer patients. The source of the very low levels of CR detected in noncancer patients is an area of ongoing intense research in the laboratory and will underpin the use of CR as a diagnostic biomarker.

Overall, CR is a prognostic tumor-derived metabolite reflecting concomitant urea cycle dysfunction and PPP hyperactivity that support cancer cell proliferation. These metabolic vulnerabilities may be exploited to identify and more effectively target aggressive CR-high tumors that have the worst prognosis in multiple cancer types.

Methods

Materials. Mass spectrometric standards were purchased from MiliporeSigma and Cambridge Isotope Laboratories. CR was custom synthesized (25).

Cell culture. All cell lines were obtained internally from the NCI-60 panel (H460, A549, A427, HCC77, SKMES1, HuH1, HuH7, Hep3B, H3122, H1975, H1650, H1299, H441, H358, H322, H233); were purchased from the American Type Culture Collection (ATCC; non-Hep3B, H3122, H1975, H1650, H1299, H441, H358, H322, H23); were prepared for LC-MS/MS analysis as described previously (24).

Liquid biospecimen preparation for metabolomics. Urine samples were prepared for LC-MS/MS analysis as described previously (24).

Cell line sample preparation for metabolomics. Culture media and cells were separately harvested in ice-cold extraction buffer (acetonitrile/H2O/methanol [65:30:5, v/v/v], 3 μM DL-2-aminopimelic acid). Cell numbers were recorded in parallel. All samples were centrifuged and supernatants were sonicated (2 min, Bioruptor, Cosmo Bio), freeze-thawed in liquid nitrogen, and filtered (Ostro Protein Precipitation Plate, Waters).

Tissue sample preparation for metabolomics. Frozen lung tissues (50–100 mg) were cryo-milled and extracted in cold extraction buffer (acetonitrile/H2O/methanol [65:30:5, v/v/v], 3 μM DL-2-aminopimelic acid). All samples were centrifuged and supernatants were collected for LC-MS/MS analysis.

LC-MS/MS metabolomics. To quantitate the metabolite levels in cancer cells, culture media, or urine, extracts prepared as described above were analyzed by ultraperformance liquid chromatography MS/MS (UPLC-MS/MS).

Metabolite quantitation was performed by multiple reaction monitoring with an Acquity UPLC/Xevo TQ-S Micro System (Waters) using a synthetic CR standard (25). For the measurement of urea cycle intermediates, the mobile phase was A:50 mM formic acid in acetonitrile and B:50 mM formic acid in water, pH 3. Separation was achieved on an Acquity UPLC BEH amide column (50 × 2.1 mm, 1.7 μm, Waters). Metabolite concentrations were calculated using calibration curves of analytical standard solutions (Masslynx, Waters) before being normalized to cell numbers.

CR levels were stratified as high or low by the median for lung tissue samples and liver cancer samples, or by the 75th percentile of the population control (i.e., cancer-free individuals) levels for urine samples from patients with lung cancer. Cell lines were classified into CR-high and CR-low groups by the median value.

To test the association of driver mutations with CR levels in cell lines, mutation data were obtained for each cell line from the Cancer Cell Line Encyclopedia, and χ2 tests were performed to assess significant associations.

Gas chromatography-coupled MS detection of ribose. Quantitative detection of ribose, glucose, and their heavy-labeled forms was performed using gas chromatography-coupled MS (GC-MS). Cell pellets and cell media were harvested in 70% (v/v) acetonitrile and DL-norleucine (10 μM) followed by homogenization (Precellys Homogenizer, Bertin Instruments). Samples were then centrifuged, and the supernatant was dried, N,O-bis(trimethylsilyl) trifluoroacetamide (BSTFA) derivatized (MiliporeSigma), and resuspended in 50 μL acetonitrile for analysis (1 μL injection).

D-ribose, U-13C3-d-ribose, D-glucose, and U-13C6-d-glucose concentrations were quantified on an Agilent 6890N gas chromatogram coupled to an Agilent 5973 mass-selective detector using standard curves (Agilent MassHunter Workstation Software). Chromatographic conditions and detection details for each ion are provided in the Supplemental Methods. RNA-Seq. Total RNA was extracted from lung tissues as previously described (67), and RNA-Seq processing was performed as outlined in the Supplemental Methods. Batch correction was performed using the Combat algorithm from the SVA package (68).

For analysis of TCGA data, RNA-Seq and clinicodemographic data on lung adenocarcinoma, lung squamous NSCLC, and HCC were downloaded from https://gdc.cancer.gov/about-data/publications/pancanatlas using survival information from (69). Corresponding mutational information was downloaded from GDAC FireHose (43, 70, 71). Projection of the CR status onto TCGA samples was performed using cancer-type-specific approaches revealed by analysis of the NCI-MD cohorts. For projection of the CR status onto TCGA adenocarcinoma and squamous NSCLC samples, (a) samples were tertile stratified according to expression of CPS1 plus NAGS, and then (b) a PPP expression score was calculated using gene set variation analysis (GSVA). NSCLC samples in the lowest tertile for CPS1 plus NAGS expression and the highest tertile for the PPP score were considered CR-high-like. NSCLC samples in the highest tertile for CPS1 plus NAGS expression and the lowest tertile for the PPP score were considered CR-low-like. For projection of the CR status onto TCGA adenocarcinoma and squamous NSCLC samples, (a) samples were tertile stratified according to expression of CPS1 plus NAGS, and then (b) a PPP expression score was calculated using gene set variation analysis (GSVA). NSCLC samples in the lowest tertile for CPS1 plus NAGS expression and the highest tertile for the PPP score were considered CR-high-like. For projection of the CR status onto TCGA adenocarcinoma and squamous NSCLC samples, (a) samples were tertile stratified according to expression of CPS1 plus NAGS, and then (b) a PPP expression score was calculated using gene set variation analysis (GSVA). NSCLC samples in the lowest tertile for CPS1 plus NAGS expression and the highest tertile for the PPP score were considered CR-low-like. HCC samples in the highest tertile for mitochondrial urea cycle activity (i.e., highest in mitochondrial urea cycle dysfunction) and the highest tertile for the PPP score were considered CR-high-like. HCC samples in the highest tertile for mitochondrial urea cycle activity (i.e., lowest in mitochondrial urea cycle dysfunction) and the lowest tertile for the PPP score were considered CR-low-like.
ways were identified using GSEA against the KEGG subset of the C2 MSigDb collection (74). Cell-type deconvolution was performed using Cibersortx and the LM22 gene signature set of hematopoietic cell subsets in bulk tissues (75, 76).

Whole-exome sequencing. Total DNA was extracted from lung tumor tissue and cell lines as described previously (67) (see also Supplemental Methods). Driver mutations and COSMIC signatures were identified using Maftools (77). Transcriptional strand mutations were annotated using MutationPatterns (78). The transcription-associated purine or pyrimidine transversion mutation bias was calculated by measuring the frequency of purine and pyrimidine transversion mutations on the transcribed strand, as described previously (30).

Global metabolomics profiling. Metabolon conducted the global metabolomics analysis of 25 matched lung tumor and adjacent non-tumor samples as described for the liver tumor samples (67) (see also Supplemental Methods). Raw metabolite abundances were median scaled for analysis. Pathway analysis was performed using metabolite correlations with CR levels by Ingenuity Pathway Analysis (QIAGEN).

Stable isotope tracing. Metabolic pathway activity in CR<sup>-</sup> and CR<sup>+</sup> cancer cells was examined by tracing stable heavy carbons from glucose through intracellular metabolite pools. Cells were cultured in phenol red-free RPMI media, 10% dialyzed serum, and U-<sup>13</sup>C-glucose (28). Cells were harvested in 80% aqueous methanol containing 500 nM 2,5-dihydroxybenzoic acid (DHB) (40 mg/mL, 70% methanol and 0.1% trifluoroacetic acid) was applied (TM Sprayer, HTX Technologies). Reconstructed ion images were generated in positive ion mode with a linear ion trap mass spectrometer equipped with a MALDI source and a nitrogen laser (LTQ XL, Thermo Fisher Scientific) using a targeted MS/MS method optimized for CR (diagnostic ion: m/z 132) (Supplemental Methods). Images were acquired at 70 μm spatial resolution using a pinwheel filter.

Cell proliferation. Cell proliferation (doubling time) and viability were measured by trypan blue dye exclusion and cell counting, as well as with the CellTiter 96 Aqueous One Assay (Promega), according to the manufacturer’s instructions.

Respirometry. The rate of oxidative phosphorylation was measured using the Agilent Seahorse XF24 Analyzer as described previously (80) and normalized to cell numbers using cell counts.

Cell-cycle analysis. Cell-cycle arrest induced by thymidine blocking was verified using a propidium iodide flow cytometry kit (Abcam) on a FACSCanto II (BD Biosciences) as described previously (81). Cell-cycle distribution was analyzed using FlowJo software (Tree Star).

OPAL multiplex immunofluorescence staining and imaging. Frozen serial sections obtained from MALDI imaging MS analysis were fixed in a formaldehyde glutaraldehyde fixative followed by antigen retrieval (Agilent Technologies, catalog S2367). Sections underwent serial staining for Ki67 (primary Ab: Cell Signaling Technology, catalog 9027; secondary Ab: Opal Polaris 480, Aoyka Biosciences); CD8 (primary Ab: Abcam, catalog ab101500; secondary Ab: Opal Polaris 780); CD68 (primary Ab: Agilent Technologies, catalog M0876; secondary Ab: Opal Polaris 620); and programmed cell death 1 (PD-1) (primary Ab: Cell Signaling Technology, catalog 43248; secondary Ab: Opal Polaris 570) as outlined in Supplemental Methods. Slides were imaged on a Vectra Polaris (Precision Medicine Group). Multiplexed images were unmixed using InForm software. Quantitative analysis of cell types was performed in QuPath (version 2.3).

Data and code availability. RNA-Seq and whole-exome sequencing data for NCI-MD lung tumors are available in the NCBI’s Gene Expression Omnibus (GEO) database (GEO GSE201221). TCGA and NCI-MD liver sample data sets (GEO GSE76297) were accessed as described above. All analyses were performed using publicly available packages as described above and in the Supplemental Methods.

Statistics. All statistical analyses were performed in GraphPad Prism 7 (GraphPad Software) or R (version 3.6.3). Differences between groups were assessed with the Mann-Whitney U test for comparison of 2 groups or the Kruskal-Wallis test with Dunn’s correction for multiple comparisons. Two-way ANOVA with Dunnett’s correction for multiple comparisons was used for comparison of 2 or more groups across multiple variables. The Benjamini-Hochberg method was used to correct for multiple comparisons for other analyses. Differences in the distribution of mutations among cell lines and their relationship with high and low CR levels were examined using Fisher’s exact test. Spearman’s tests were used to determine correlations. Survival analysis was performed using the R packages Survminer and Survival. Data presented as box plots show the median, box boundaries indicate the 25th and 75th percentiles, and whiskers show the minimum to maximum values. A P value of less than 0.05 was considered statistically significant.

Study approval. Lung tumor and non-tumor biospecimens from the NCI-MD cohort were collected according to procedures approved by the NCI, NIH, as described previously (21) (IRB OH98-C-N027). Liver cancer biospecimens and data were obtained from the TIGER-LC cohort as described previously (24, 67). Written informed consent from patients was received prior to participation in these studies. The clinicodemographic features of these cohorts are outlined in Supplemental Tables 1, 3, and 4.

Author contributions

ALP and CCH conceptualized the study. ALP, TO, MR, DB, and SK designed the methodology. ALP, LT, TO, DP, and MR conducted the formal analysis. ALP, LT, TO, YK, DP, TT, ST, JAB, MR, DB, and KWK performed experiments. EB, GTP, FJG, SPH, SA, BMR, XWW, and CCH provided resources. EB curated the data.

ALP wrote the original draft of the manuscript. Review and Editing ALP, LT, TO, EB, SK, FJG, SPH, SA, BMR, XWW, and CCH reviewed and edited the manuscript. ALP performed visualization. CCH supervised the study, handled project administration, and acquired funding.

Acknowledgments

The authors gratefully acknowledge the assistance and expertise of Caroline Lewis and Bena Chan of the Whitehead Institute Metabo-
omics Core at the Massachusetts Institute of Technology for assistance with stable isotope tracing studies. We also acknowledge the contributions of the staff of the NCI and the University of Maryland in providing clinicodemographic data and sourcing biospecimens. We acknowledge the expert advice of Justin Lacks of the Center for Cancer Research Collaborative Bioinformatics Resource in processing RNA-Seq and whole-exome sequencing data. The authors gratefully acknowledge Majda Haznadar and Anu Budhu for generously providing the transcriptomic, metabolomic, and clinicodemographic data on liver cancer tumors. The authors also gratefully acknowledge the assistance of Houssain Sater (The Cleveland Clinic, Cleveland, Ohio, USA; formerly at the NCI) and Wiem Lassoued (NCI) for assistance in scanning the multiplex imaging slides, as well as Iveta Slapetova of the Katharina Gaus Light Microscopy Facility at the University of New South Wales for expertise and assistance with analyzing the multiplexed images.

Address correspondence to: Curtis C. Harris, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, 37 Convent Dr., Bethesda, Maryland 20892, USA. Phone: 240.760.6420; Email: harrisc@mail.nih.gov. Or to: Amelia L. Parker, Cancer Matrix and Metastasis Laboratory, Garvan Institute of Medical Research, 384 Victoria St., Darlinghurst, New South Wales, Australia. 2010. Phone: 612.9355.5716; Email: am.parker@garvan.org.au.

ALP’s present address is: Garvan Institute of Medical Research, Sydney, Australia.

1. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012;21(3):297–308.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
3. Vander Heiden MG, DeBerardinis RJ. Understanding the intersections between metabolism and cancer biology. Cell. 2017;168(4):657–669.
4. Fan TWM, et al. Altered regulation of metabolic plasticity and flexibility dynamics for cancer therapy. Cancer Discov. 2020;10(12):1797–1807.
5. Keshet R, et al. Rewiring urea cycle metabolism and the urea cycle. Nat Rev Cancer. 2018;18(10):634–645.
6. Wang M, et al. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27(8):1345–1356.
7. Redman MW, et al. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. Lancet Oncol. 2020;21(12):1589–1601.
8. Faust B, et al. Metabolic reprogramming and cancer progression. Science. 2020;368(6487):eaaw5473.
9. Lane AN, Fan TW-M. Regulation of mammalian nucleotide metabolism and biosynthesis. Nucleic Acids Res. 2015;43(4):2466–2485.
10. Fan TWM, et al. Altered regulation of metabolic pathways in human lung cancer discerned by (13) C stable isotope-resolved metabolomics (SIRM). Mol Cancer. 2009;8:41.
11. Sellers K, et al. Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation. J Clin Invest. 2015;125(2):687–698.
12. Chen PH, et al. Metabolic diversity in human non-small cell lung cancer cells. Mol Cell. 2019;76(5):838–851.
13. Christen S, et al. Breast cancer-derived lung metastases show increased pyruvate carboxylase-dependent anaplerosis. Cell Rep. 2016;17(3):837–848.
14. Hung MH, et al. Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma. Nat Commun. 2021;12(1):1455.
15. Rosario SR, et al. Pan-cancer analysis of transcriptional metabolic dysregulation using The Cancer Genome Atlas. Nat Commun. 2018;9(1):5330.
16. Gagliò D, et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol. 2011;7:523.
17. Cantor JR, Sabatini DM. Cancer cell metabolism: one hallmark, many faces. Cancer Discov. 2012;2(10):881–898.
18. Delage B, et al. Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer. 2010;126(2):2762–2772.
19. Salosarek PW, et al. Phase I, pharmacogenomic, dose-expansion study of pegylarginase plus metformin and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer. Cancer Med. 2021;10(19):6642–6652.
20. Chan SL, et al. A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepaticcellular carcinoma. Invest New Drugs. 2021;39(5):1375–1382.
21. Mathe EA, et al. Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer. Cancer Res. 2014;74(12):3259–3270.
22. Haznadar M, et al. Urinary metabolite risk biomarkers of lung cancer: a prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2016;25(6):978–986.
23. Patel D, et al. Unique and novel urinary metabolomic features in malignant versus benign adrenal neoplasms. Clin Cancer Res 2017;23(17):5302–5310.
24. Haznadar M, et al. Urinary metabolites diagnostic and prognostic of intrahepatic cholangiocarcinoma. Cancer Epidemiol Biomarkers Prev. 2019;28(10):1704–1711.
25. Patel DP, et al. Improved detection and precise relative quantification of the urinary cancer metabolite biomarkers - creatine riboside, creatinine riboside, creatine and creatinine by UPLC-ESI-MS/MS: Application to the NCI-Maryland cohort population controls and lung cancer cases. J Pharm Biomed Anal. 2020;191:113596.
26. Tammemägi MC, et al. Development and validation of a multivariable lung cancer risk prediction model that includes low-dose computed tomography screening results: a secondary analysis of data from the National Lung Screening Trial. JAMA Netw Open. 2019;2(3):e190204.
27. Brosnan JT, Brosnan ME. Creatine metabolism and the urea cycle. Mol Genet Metab. 2010;100(Suppl 1):S49–S52.
28. Cantor JR, et al. Physiologic medium rewires cellular metabolism and reveals uric acid as an endogenous inhibitor of UMP synthase. Cell. 2012;169(2):258–272.
29. Kim J, et al. CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells. Nature. 2017;546(7656):168–172.
30. Lee JS, et al. Urea cycle dysregulation generates clinically relevant genomic and biochemical signatures. Cell. 2018;174(6):1559–1570.
31. Rabinovich S, et al. The mitochondrial carrier Citrin plays a role in regulating cellular energy during carcinogenesis. Oncogene. 2020;39(1):164–175.
32. Birsoy K, et al. An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis. Cell. 2015;162(3):540–551.
33. Sullivan LB, et al. Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells. Cell. 2015;162(3):552–563.
34. Campbell JD, et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 2016;48(6):607–616.
35. Dai F, et al. The number and microlocalization of tumor-associated immune cells are associated with patient’s survival time in non-small cell lung cancer. BMC Cancer. 2010;10:220.
36. Bremnes RM, et al. The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer. J Thorac Oncol. 2016;11(6):789–800.
37. Rabinovich S, et al. Disruption of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis. Nature. 2015;527(7578):379–383.
38. Gonzalez-Magaña A, Blanco FJ. Human PCNA structure, function and interactions. Biomolecules. 2020;10(4):570.
39. Çeliktas M, et al. Role of CPS1 in cell growth, proliferation, and cancer. Nature. 2018;174(6):1559–1570.
40. Gao Y, et al. Quantitative proteomics by SWATH-MS reveals sophisticated metabolic reprogramming in hepatocellular carcinoma tissues. Sci Rep. 2017;7:45913.
41. Liu H, et al. DNA methylation suppresses expres-
sion of the urea cycle enzyme carbamoyl phospho-
phosphate synthetase 1 (CPS1) in human hepatocellu-
lar carcinoma. Am J Pathol. 2011;178(2):652–661.
42. Ma SL, et al. Co-expression of the carbamoyl-
phosphate synthase 1 gene and its long non-
coding RNA correlates with poor prognosis of
patients with intrahepatic cholangiocarcinoma.
Mol Med Rep. 2013;12(6):7915–7926.
43. Wheeler DA, et al. Comprehensive and integra-
tive genomic characterization of hepatocellular
carcinoma. Cell. 2017;169(7):1327–1341.
44. Papalazarou V, et al. The creatine-phosphagen
system is mechaoresponsive in pancreatic ade-
ocarcinoma and fuels invasion and metastasis.
Nat Metab. 2020;2(1):62–80.
45. Adam J, et al. A role for cytosolic fumarate
hydratase in urea cycle metabolism and renal
neoplasia. Cell Rep. 2013;3(5):1440–1448.
46. Cheng CT, et al. Arginase starvation kills tumor
cells through aspartate starvation and mito-
chondrial dysfunction. Commun Biol. 2018;1:178.
47. Bateman LA, et al. Argininosuccinate synthase 1 is
a metabolic regulator of colorectal cancer patho-
genicity. ACS Chem Biol. 2017;12(4):905–911.
48. Vincent MF, et al. Inhibition by AICA riboside of
glucoseogenesis in isolated rat hepatocytes. Dia-
abetes. 1991;40(10):1259–1266.
49. Jiang P, et al. Regulation of the pentose phosphate
pathway in cancer. Protein Cell. 2014;5(8):592–602.
50. Demicheli R, et al. Recurrence dynamics for
non-small-cell lung cancer: effect of surgery on
sequential molecular carcinogenetic events.
Nat Commun. 2019;25(5):517–525.
51. Takahashi H, et al. Tobacco smoke promotes
lung tumorigenesis by triggering IKKbeta- and
JNK1-dependent inflammation. Cancer Cell.
2010;17(1):89–97.
52. Lemičjbar H, et al. Tobacco smoke-induced lung
cell proliferation by tumor necrosis factor
alpha-converting enzyme and amphiregulin.
J Biol Chem. 2003;278(28):26202–26207.
53. Rangasamy T, et al. Genetic ablation of Nrf2
enhances susceptibility to cigarette smoke-
induced emphysema in mice. J Clin Invest.
2004;114(9):1248–1259.
54. Best SA, et al. Synergy between the KEAP1/NRF2
and PI3K pathways drives non-small-cell lung
cancer with an altered immune microenviron-
ment. Cell Metab. 2018;27(4):935–943.
55. Reddell RR, et al. Development of tumorigenic-
ness in simian virus 40-immortalized human
bronchial epithelial cell lines. Cancer Res.
1993;53(5):985–991.
56. Reddell RR, et al. SV40-induced immortalization
and ras-transformation of human bronchial ep-
ithelial cells. Int J Cancer. 1995;61(2):199–205.
57. Chaisangmongkol J, et al. Common molecular
subtypes among Asian hepatocellular carci-
noma and cholangiocarcinoma. Cancer Cell.
2017;32(1):57–70.
58. Leek JT, et al. The sva package for removing
batch effects and other unwanted variation in
high-throughput experiments. Bioinformatics.
2012;28(6):882–883.
59. Liu J, et al. An integrated TCGA pan-cancer clini-
cal data resource to drive high-quality survival
outcome analytics. Cell. 2018;173(2):400–416.
60. Jiang P, et al. Regulation of the pentose phosphate
pathway in cancer. Protein Cell. 2014;5(8):592–602.
61. Takahashi H, et al. Tobacco smoke promotes
lung tumorigenesis by triggering IKKbeta- and
JNK1-dependent inflammation. Cancer Cell.
2010;17(1):89–97.
62. Lemičjbar H, et al. Tobacco smoke-induced lung
cell proliferation by tumor necrosis factor
alpha-converting enzyme and amphiregulin.
J Biol Chem. 2003;278(28):26202–26207.
63. Rangasamy T, et al. Genetic ablation of Nrf2
enhances susceptibility to cigarette smoke-
induced emphysema in mice. J Clin Invest.
2004;114(9):1248–1259.
64. Best SA, et al. Synergy between the KEAP1/NRF2
and PI3K pathways drives non-small-cell lung
cancer with an altered immune microenviron-
ment. Cell Metab. 2018;27(4):935–943.
65. Reddell RR, et al. Development of tumorigenic-
ness in simian virus 40-immortalized human
bronchial epithelial cell lines. Cancer Res.
1993;53(5):985–991.
66. Reddell RR, et al. SV40-induced immortalization
and ras-transformation of human bronchial ep-
ithelial cells. Int J Cancer. 1995;61(2):199–205.
67. Chaisangmongkol J, et al. Common molecular
subtypes among Asian hepatocellular carci-
noma and cholangiocarcinoma. Cancer Cell.
2017;32(1):57–70.
68. Leek JT, et al. The sva package for removing
batch effects and other unwanted variation in
high-throughput experiments. Bioinformatics.
2012;28(6):882–883.
69. Liu J, et al. An integrated TCGA pan-cancer clini-
cal data resource to drive high-quality survival
outcome analytics. Cell. 2018;173(2):400–416.
70. Cancer Genome Atlas Research Network.
Comprehensive genomic characteriza-
tion of squamous cell lung cancers. Nature.
2012;489(741):519–525.
71. Cancer Genome Atlas Research Network. Com-
prehensive molecular profiling of lung adeno-
carcinoma. Nature. 2014;511(7511):543–550.
72. McCarthy DJ, et al. Differential expression anal-
ysis of multifactor RNA-Seq experiments with
respect to biological variation. Nucleic Acids Res.
2012;40(10):4288–4297.
73. Ritchie ME, et al. Limma powers differential
expression analyses for RNA-sequencing and
microarray studies. Nucleic Acids Res.
2015;43(7):e47.
74. Subramanian A, et al. Gene set enrichment analy-
sis: a knowledge-based approach for interpreting
genome-wide expression profiles. Proc Natl Acad
Sci U S A. 2005;102(43):15545–15550.
75. Newman AM, et al. Determining cell type abun-
dance and expression from bulk tissues with digi-
tal cytometry. Nat Biotechnol. 2019;37(7):773–782.
76. Newman AM, et al. Robust enumeration of cell
subsets from tissue expression profiles. Nat Meth-
ds. 2015;12(5):453–457.
77. Mayakonda A, et al. Maftools: efficient and com-
prehensive analysis of somatic variants in cancer.
Genome Res. 2015;43(7):e47.
78. Subramanian A, et al. Gene set enrichment analy-
sis: a knowledge-based approach for interpreting
genome-wide expression profiles. Proc Natl Acad
Sci U S A. 2005;102(43):15545–15550.